Molecular profiling studies have established a common signature for sBL that distinguishes it from other types of Myc-translocated and Myc-activated DLBCL [20–22], and have also provided evidence for subtypes within sBL, e.g. those with or without activating mutations in ID3. The gene discussed is ID3; the disease is diffuse large B-cell lymphoma.